• Content Type

Strategies and roadmaps

Artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan

Overview

The U.S. Food and Drug Administration (FDA) issued the “Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan” from the Center for Devices and Radiological Health’s Digital Health Center of Excellence. The Action Plan is a direct response to stakeholder feedback to the April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device” and outlines five actions the FDA intends to take.

Key Information

Date published: 1 Jan 2021

Categorisation

Discussion forum

  • Author
    Posts
  • Up
    0
    ::

    Share your thoughts on this item here.

You must be logged in to contribute to the discussion

Login